PLaN Therapeutics

Biotechnology Research • Zuidrak 8, Wieringerwerf, Netherlands • 1-10 Employees

Company overview

Headquarters	Zuidrak 8, Wieringerwerf, North Holland 1771 SW, NL
Website	plantherapeutics.com
NAICS	541714
Employees	1-10

Key Contact at PLaN Therapeutics

Pavlina Konstantinova

Chief Executive Officer

PLaN Therapeutics Email Formats

PLaN Therapeutics uses 1 email format. The most common is {first name} (e.g., john@plantherapeutics.com), used 100% of the time.

Format	Example	Percentage
{first name}	john@plantherapeutics.com	100%

About PLaN Therapeutics

We bring an affordable treatment for heart muscle disease PLN from the lab to the patient. We do this in close collaboration with the PLN Foundation. The foundation's goal is to find an affordable treatment for the disease as quickly as possible. We join in by getting this possible treatment to the patient. Calcium ions in the heart muscle cells are important for our heart to beat. The protein phospholamban (PLN) plays an important role in the calcium metabolism of heart muscle cells. In 2010, a mutation (change in DNA) in the PLN gene was linked to the development of heart muscle disease in the Netherlands. The Dutch mutation concerns the absence of the amino acid arginine (Arg) at position 14 and is therefore called in scientific terms: PLN p.Arg14del (1). Our job is to bring scientific breakthroughs from the lab to the patient. For us, this means: developing an affordable treatment for PLN. We work closely with the foundation for research into these new treatments. The work that comes next is our responsibility.

PLaN Therapeutics revenue & valuation

Annual revenue	$256,665
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$821,328
Total funding	No funding